R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

NCT03213977 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

475

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: R-DA-EPOCH
DRUG: R-CEOP90

Sponsor

Fujian Medical University